GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	EGP 385.00	+1.58%	15,82,397
08/26/08	EGP 379.00	+19.96%	9,29,268
05/26/05	EGP 315.93	+1.90%	3,64,073
04/26/04	EGP 310.03	+1.65%	6,80,040
03/26/03	EGP 305.00	+15.53%	4,94,893

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 09/11/2026			5-day change	1st Jan Change
385.00 ^EGP	+1.58%		+45.83%	+504.87%

13/08	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
17/05	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE

Market Cap	3.22TCr 60Cr 53Cr 49Cr 44Cr 84Cr 5.59TCr 86Cr 586.29Cr 233.68Cr 2.99TCr 223.97Cr 219.17Cr 9.43TCr	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	3.18TCr 59Cr 53Cr 48Cr 44Cr 83Cr 5.52TCr 85Cr 579.03Cr 230.79Cr 2.96TCr 221.19Cr 216.46Cr 9.31TCr	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024	2.78%	Yield 2025	1.18%

13/08	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
17/05	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
12/03	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/03	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
12/03	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
30/12	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
19/11	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
12/25/12	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/25/12	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/25/14	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/25/14	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/25/09	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

10/22/10	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/21/20	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Share Price

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news: GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Price Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+1.58%
1 week	+45.83%
Current month	+32.44%
1 month	+16.67%
3 months	-19.33%
6 months	+434.87%
Current year	+504.87%

1 week	305	415
1 month	212.05	415
Current year	55.1	609
1 year	55.1	609
3 years	24.7	609
5 years	18.7	609
10 years	0	609

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	+1.58%	+45.83%	+464.43%	+1,107.65%	60Cr
ELI LILLY AND COMPANY	+4.28%	+0.07%	+52.75%	+138.78%	1,25800Cr
JOHNSON & JOHNSON	+2.13%	+4.27%	+51.21%	+91.36%	68TCr
ABBVIE INC.	+0.68%	+1.54%	+33.83%	+112.47%	52TCr
ROCHE HOLDING AG	-0.37%	+2.10%	+43.13%	+68.62%	39TCr
MERCK & CO., INC.	+1.38%	+0.27%	+72.42%	+45.30%	37TCr
NOVARTIS AG	+0.35%	+1.99%	+31.23%	+59.93%	31TCr
ASTRAZENECA PLC	-0.55%	+1.75%	+6.66%	+38.75%	29TCr
AMGEN INC.	+1.04%	-0.05%	+45.29%	+76.18%	25TCr
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+42.48%	+125.82%	21TCr
Average	+0.57%	+3.57%	+84.34%	+186.49%	43TCr
Weighted average by Cap.	+0.47%	+1.18%	+45.43%	+96.93%

	2024	2025
Net sales	299.08Cr 5.55Cr 4.95Cr 4.56Cr 4.14Cr 7.84Cr 520.26Cr 8.04Cr 55Cr 22Cr 278.53Cr 21Cr 20Cr 877.25Cr	373.05Cr 6.92Cr 6.18Cr 5.69Cr 5.16Cr 9.78Cr 648.93Cr 10Cr 68Cr 27Cr 347.42Cr 26Cr 25Cr 1.09TCr
Net income	17Cr 32.29L 28.82L 26.52L 24.07L 45.61L 30Cr 46.75L 3.17Cr 1.26Cr 16Cr 1.21Cr 1.19Cr 51Cr	21Cr 39.57L 35.32L 32.5L 29.5L 55.9L 37Cr 57.29L 3.89Cr 1.55Cr 20Cr 1.49Cr 1.45Cr 63Cr
Net Debt	4.4Cr 8L 7L 7L 6L 11.54L 7.66Cr 11.82L 80.25L 31.98L 4.1Cr 30.65L 30L 13Cr	-40Cr -73.85L -65.92L -60.66L -55.05L -1.04Cr -69Cr -1.07Cr -7.26Cr -2.89Cr -37Cr -2.77Cr -2.71Cr -116.72Cr